Mersana Therapeutics (MRSN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

MRSN Stock Forecast

Mersana Therapeutics stock forecast is as follows: an average price target of $3.00 (represents a 87.50% upside from MRSN’s last price of $1.60) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

MRSN Price Target

The average price target for Mersana Therapeutics (MRSN) is $3.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential 87.50% upside from MRSN's last price of $1.60.

MRSN Analyst Ratings

Buy

According to 5 Wall Street analysts, Mersana Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for MRSN stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Mersana Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 14, 2024	Collen Kusy	Robert W. Baird	$3.00	$1.35	122.22%	87.50%

The latest Mersana Therapeutics stock forecast, released on Aug 14, 2024 by Collen Kusy from Robert W. Baird, set a price target of $3.00, which represents a 122.22% increase from the stock price at the time of the forecast ($1.35), and a 87.50% increase from MRSN last price ($1.60).

Mersana Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$3.00
Last Closing Price	$1.60	$1.60	$1.60
Upside/Downside	-100.00%	-100.00%	87.50%

In the current month, the average price target of Mersana Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Mersana Therapeutics's last price of $1.60. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 15, 2024	Citigroup	Buy	Buy	Initialise
Feb 29, 2024	Guggenheim	Underperform	Underperform	Hold
Feb 29, 2024	Wedbush	Buy	Buy	Hold
Feb 29, 2024	Wedbush		Outperform	Upgrade
Feb 28, 2024	BTIG		Buy	Upgrade
Dec 04, 2023	Citigroup		Buy	Upgrade
Jul 27, 2023	Piper Sandler		Overweight	Initialise
Jul 27, 2023	Scotiabank		Sector Outperform	Initialise
Jun 15, 2023	Guggenheim		Buy	Initialise
Feb 18, 2022	SVB Leerink	Outperform	Outperform	Hold

Mersana Therapeutics's last stock rating was published by Citigroup on Nov 15, 2024. The company gave MRSN a "Buy" rating, the same as its previous rate.

Mersana Therapeutics Financial Forecast

Mersana Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$10.70M	-	$10.65M	$7.80M	$14.69M	$5.57M	$4.28M	$2.04M	$11.00K	$11.00K	$11.00K	$11.00K	$11.00K	$11.00K	$796.00K	$11.00K	$42.00K	$844.00K
Avg Forecast	$9.08M	$9.42M	$9.76M	$10.13M	$6.09M	$6.05M	$6.01M	$5.90M	$7.64M	$7.53M	$8.72M	$8.50M	$14.74M	$9.60M	$12.93M	$14.00M	$15.28M	$56.78M	$2.20M	$17.24M	$5.33K	$120.50K	$170.00K	$312.80K	$202.20K	$439.20K	$306.00K	$390.67K	$583.33K	$350.00K
High Forecast	$12.77M	$13.24M	$13.73M	$14.24M	$8.57M	$8.51M	$8.46M	$6.24M	$12.73M	$10.59M	$8.72M	$11.96M	$29.54M	$9.75M	$18.18M	$19.69M	$21.49M	$56.78M	$2.20M	$17.24M	$5.33K	$120.50K	$170.00K	$312.80K	$202.20K	$439.20K	$306.00K	$390.67K	$583.33K	$350.00K
Low Forecast	$4.20M	$4.36M	$4.52M	$4.69M	$2.82M	$2.80M	$2.78M	$5.54M	$1.19M	$3.48M	$8.72M	$3.94M	$7.12M	$9.45M	$5.99M	$6.48M	$7.08M	$56.78M	$2.20M	$17.24M	$5.33K	$120.50K	$170.00K	$312.80K	$202.20K	$439.20K	$306.00K	$390.67K	$583.33K	$350.00K
# Analysts	1	1	1	1	1	1	1	3	7	3	3	3	6	3	3	3	4	4	4	4	3	3	3	3	9	9	9	9	8	8
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.73%	-	0.82%	0.56%	0.96%	0.10%	1.95%	0.12%	2.06%	0.09%	0.06%	0.04%	0.05%	0.03%	2.60%	0.03%	0.07%	2.41%

Mersana Therapeutics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $8.50M, with a low forecast of $3.94M, and a high forecast of $11.96M. MRSN's average Quarter revenue forecast represents a -20.54% decrease compared to the company's last Quarter revenue of $10.70M (Dec 23).

Mersana Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	7	3	3	3	6	3	3	3	4	4	4	4	3	3	3	3	9	9	9	9	8	8
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-19.00M	-	$-54.31M	$-54.86M	$-45.83M	$-59.64M	$-51.23M	$-46.33M	$-47.79M	$-45.16M	$-40.61M	$-34.37M	$-28.49M	$-22.14M	$-19.45M	$-16.59M	$-15.88M	$-16.38M
Avg Forecast	$-8.42M	$-8.73M	$-9.05M	$-9.39M	$-5.65M	$-5.61M	$-5.58M	$-5.47M	$-7.08M	$-6.98M	$-8.08M	$-34.46M	$-13.66M	$-8.90M	$-11.98M	$-36.85M	$-44.02M	$-52.97M	$-2.05M	$-39.41M	$-4.97K	$-112.40K	$-158.58K	$-24.68M	$-188.62K	$-409.69K	$-285.44K	$-17.49M	$-544.14K	$-326.49K
High Forecast	$-3.90M	$-4.04M	$-4.19M	$-4.35M	$-2.61M	$-2.60M	$-2.58M	$-5.14M	$-1.10M	$-3.23M	$-8.08M	$-27.56M	$-6.60M	$-8.76M	$-5.55M	$-29.48M	$-35.21M	$-52.97M	$-2.05M	$-31.53M	$-4.97K	$-112.40K	$-158.58K	$-19.74M	$-188.62K	$-409.69K	$-285.44K	$-13.99M	$-544.14K	$-326.49K
Low Forecast	$-11.84M	$-12.27M	$-12.73M	$-13.20M	$-7.94M	$-7.89M	$-7.84M	$-5.79M	$-11.80M	$-9.81M	$-8.08M	$-41.35M	$-27.38M	$-9.04M	$-16.86M	$-44.22M	$-52.82M	$-52.97M	$-2.05M	$-47.30M	$-4.97K	$-112.40K	$-158.58K	$-29.61M	$-188.62K	$-409.69K	$-285.44K	$-20.98M	$-544.14K	$-326.49K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.39%	-	4.53%	1.49%	1.04%	1.13%	24.94%	1.18%	9608.16%	401.77%	256.10%	1.39%	151.05%	54.04%	68.15%	0.95%	29.18%	50.16%

undefined analysts predict MRSN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Mersana Therapeutics's previous annual EBITDA (undefined) of $NaN.

Mersana Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	7	3	3	3	6	3	3	3	4	4	4	4	3	3	3	3	9	9	9	9	8	8
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-18.56M	-	$-54.31M	$-57.15M	$-45.89M	$-60.69M	$-52.98M	$-47.98M	$-49.96M	$-45.47M	$-40.91M	$-34.69M	$-28.84M	$-22.49M	$-19.79M	$-16.93M	$-16.25M	$-16.79M
Avg Forecast	$-21.06M	$-20.67M	$-20.65M	$-22.65M	$-21.84M	$-22.58M	$-22.83M	$-23.56M	$-18.36M	$-21.07M	$-20.46M	$-35.15M	$-19.66M	$-43.91M	$-53.56M	$-37.59M	$-45.12M	$484.61K	$-61.84M	$-40.20M	$-79.79M	$-69.01M	$-59.09M	$-24.91M	$-38.68M	$-37.03M	$-35.42M	$-17.84M	$-46.34M	$-45.33M
High Forecast	$-6.36M	$-6.24M	$-6.23M	$-6.84M	$-6.59M	$-6.82M	$-6.89M	$-17.36M	$-12.62M	$-6.36M	$-6.18M	$-28.12M	$-13.76M	$-13.25M	$-16.16M	$-30.07M	$-36.09M	$484.61K	$-61.84M	$-32.16M	$-79.79M	$-69.01M	$-59.09M	$-19.93M	$-38.68M	$-37.03M	$-35.42M	$-14.27M	$-46.34M	$-45.33M
Low Forecast	$-32.19M	$-31.58M	$-31.57M	$-34.62M	$-33.39M	$-34.51M	$-34.89M	$-28.52M	$-24.10M	$-32.20M	$-31.28M	$-42.18M	$-25.55M	$-67.11M	$-81.85M	$-45.11M	$-54.14M	$484.61K	$-61.84M	$-48.24M	$-79.79M	$-69.01M	$-59.09M	$-29.89M	$-38.68M	$-37.03M	$-35.42M	$-21.41M	$-46.34M	$-45.33M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.94%	-	1.01%	1.52%	1.02%	-125.24%	0.86%	1.19%	0.63%	0.66%	0.69%	1.39%	0.75%	0.61%	0.56%	0.95%	0.35%	0.37%

Mersana Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MRSN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Mersana Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	7	3	3	3	6	3	3	3	4	4	4	4	3	3	3	3	9	9	9	9	8	8
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$10.13M	-	$18.19M	$18.33M	$14.80M	$14.57M	$14.80M	$12.78M	$10.67M	$10.12M	$8.88M	$7.21M	$5.91M	$5.88M	$5.17M	$4.94M	$4.21M	$4.44M
Avg Forecast	$1.61B	$1.67B	$1.74B	$1.80B	$1.08B	$1.08B	$1.07B	$1.05B	$1.36B	$1.34B	$1.55B	$1.51B	$2.62B	$1.71B	$2.30B	$10.17M	$9.83M	$10.09B	$391.27M	$10.87M	$947.61K	$21.41M	$30.21M	$55.58M	$35.93M	$78.04M	$54.37M	$69.42M	$103.65M	$62.19M
High Forecast	$2.27B	$2.35B	$2.44B	$2.53B	$1.52B	$1.51B	$1.50B	$1.11B	$2.26B	$1.88B	$1.55B	$2.12B	$5.25B	$1.73B	$3.23B	$12.20M	$11.80M	$10.09B	$391.27M	$13.05M	$947.61K	$21.41M	$30.21M	$55.58M	$35.93M	$78.04M	$54.37M	$69.42M	$103.65M	$62.19M
Low Forecast	$746.88M	$774.56M	$803.27M	$833.04M	$501.24M	$498.01M	$494.80M	$984.94M	$211.49M	$619.27M	$1.55B	$699.43M	$1.26B	$1.68B	$1.06B	$8.13M	$7.86M	$10.09B	$391.27M	$8.70M	$947.61K	$21.41M	$30.21M	$55.58M	$35.93M	$78.04M	$54.37M	$69.42M	$103.65M	$62.19M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	-	0.01%	1.80%	1.51%	0.00%	0.04%	1.18%	11.26%	0.47%	0.29%	0.13%	0.16%	0.08%	0.10%	0.07%	0.04%	0.07%

Mersana Therapeutics's average Quarter SG&A projection for Mar 24 is $1.51B, based on 3 Wall Street analysts, with a range of $699.43M to $2.12B. The forecast indicates a 14808.84% rise compared to MRSN last annual SG&A of $10.13M (Dec 23).

Mersana Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	7	3	3	3	6	3	3	3	4	4	4	4	3	3	3	3	9	9	9	9	8	8
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.13	-	$-0.47	$-0.53	$-0.45	$-0.62	$-0.55	$-0.60	$-0.69	$-0.63	$-0.59	$-0.50	$-0.42	$-0.33	$-0.33	$-0.35	$-0.34	$-0.35
Avg Forecast	$-0.17	$-0.17	$-0.17	$-0.18	$-0.18	$-0.18	$-0.19	$-0.19	$-0.15	$-0.17	$-0.17	$-0.18	$-0.16	$-0.36	$-0.44	$-0.43	$-0.49	-	$-0.51	$-0.31	$-0.66	$-0.57	$-0.49	$-0.39	$-0.32	$-0.30	$-0.29	$-0.37	$-0.38	$-0.37
High Forecast	$-0.05	$-0.05	$-0.05	$-0.06	$-0.05	$-0.06	$-0.06	$-0.14	$-0.10	$-0.05	$-0.05	$-0.05	$-0.11	$-0.11	$-0.13	$-0.13	$-0.15	-	$-0.51	$-0.31	$-0.66	$-0.57	$-0.49	$-0.39	$-0.32	$-0.30	$-0.29	$-0.37	$-0.38	$-0.37
Low Forecast	$-0.26	$-0.26	$-0.26	$-0.28	$-0.27	$-0.28	$-0.28	$-0.23	$-0.20	$-0.26	$-0.25	$-0.27	$-0.21	$-0.55	$-0.67	$-0.65	$-0.76	-	$-0.51	$-0.31	$-0.66	$-0.57	$-0.49	$-0.39	$-0.32	$-0.30	$-0.29	$-0.37	$-0.38	$-0.37
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.81%	-	1.08%	1.24%	0.91%	-155.35%	1.08%	1.94%	1.05%	1.11%	1.21%	1.27%	1.32%	1.08%	1.13%	0.95%	0.89%	0.94%

According to undefined Wall Street analysts, Mersana Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MRSN previous annual EPS of $NaN (undefined).

Mersana Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
RLAY	Relay Therapeutics	$4.50	$18.00	300.00%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
CGEM	Cullinan Oncology	$11.49	$34.00	195.91%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
PLRX	Pliant Therapeutics	$14.37	$35.50	147.04%	Buy
KURA	Kura Oncology	$9.74	$23.33	139.53%	Buy
SNDX	Syndax Pharmaceuticals	$13.63	$31.67	132.36%	Buy
RCUS	Arcus Biosciences	$16.08	$31.71	97.20%	Buy
AMLX	Amylyx Pharmaceuticals	$4.28	$8.25	92.76%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
MRUS	Merus	$44.90	$81.25	80.96%	Buy
REPL	Replimune Group	$11.72	$19.00	62.12%	Buy
MRSN	Mersana Therapeutics	$2.03	$3.00	47.78%	Buy
RVMD	Revolution Medicines	$45.16	$65.67	45.42%	Buy
PTGX	Protagonist Therapeutics	$40.69	$57.33	40.89%	Buy
HOOK	HOOKIPA Pharma	$2.13	$3.00	40.85%	Buy
VRDN	Viridian Therapeutics	$20.82	$22.75	9.27%	Buy

MRSN Forecast FAQ

Is Mersana Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, Mersana Therapeutics (MRSN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of MRSN's total ratings.

What is MRSN's price target?

Mersana Therapeutics (MRSN) average price target is $3 with a range of $3 to $3, implying a 87.50% from its last price of $1.6. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Mersana Therapeutics stock go up soon?

According to Wall Street analysts' prediction for MRSN stock, the company can go up by 87.50% (from the last price of $1.6 to the average price target of $3), up by 87.50% based on the highest stock price target, and up by 87.50% based on the lowest stock price target.

Can Mersana Therapeutics stock reach $2?

MRSN's average twelve months analyst stock price target of $3 supports the claim that Mersana Therapeutics can reach $2 in the near future.

What are Mersana Therapeutics's analysts' financial forecasts?

Mersana Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $24.06M (high $31.78M, low $13.95M), average EBITDA is $-22.301M (high $-12.931M, low $-29.461M), average net income is $-90.814M (high $-37.659M, low $-131M), average SG&A $4.28B (high $5.65B, low $2.48B), and average EPS is $-0.74 (high $-0.307, low $-1.07). MRSN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $38.39M (high $53.99M, low $17.77M), average EBITDA is $-35.581M (high $-16.472M, low $-50.041M), average net income is $-85.034M (high $-25.665M, low $-130M), average SG&A $6.82B (high $9.59B, low $3.16B), and average EPS is $-0.693 (high $-0.209, low $-1.059).

Did the MRSN's actual financial results beat the analysts' financial forecasts?

Based on Mersana Therapeutics's last annual report (Dec 2023), the company's revenue was $36.86M, which missed the average analysts forecast of $51.27M by -28.12%. Apple's EBITDA was $-172M, beating the average prediction of $-71.399M by 140.44%. The company's net income was $-172M, beating the average estimation of $-155M by 10.96%. Apple's SG&A was $59.54M, missing the average forecast of $6.63B by -99.10%. Lastly, the company's EPS was $-1.48, beating the average prediction of $-1.382 by 7.06%. In terms of the last quarterly report (Dec 2023), Mersana Therapeutics's revenue was $10.7M, missing the average analysts' forecast of $14.74M by -27.40%. The company's EBITDA was $-18.998M, beating the average prediction of $-13.663M by 39.04%. Mersana Therapeutics's net income was $-18.561M, missing the average estimation of $-19.656M by -5.57%. The company's SG&A was $10.13M, missing the average forecast of $2.62B by -99.61%. Lastly, the company's EPS was $-0.13, missing the average prediction of $-0.16 by -18.84%